Institution
Shahid Beheshti University of Medical Sciences and Health Services
Education•Tehran, Iran•
About: Shahid Beheshti University of Medical Sciences and Health Services is a education organization based out in Tehran, Iran. It is known for research contribution in the topics: Population & Medicine. The organization has 19456 authors who have published 33659 publications receiving 365676 citations.
Topics: Population, Medicine, Cancer, Breast cancer, Randomized controlled trial
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Results showed contamination of the ICU environments and HCWs with important bacterial pathogens that are the main risk factors for HAIs in the studied hospitals.
94 citations
••
French Institute of Health and Medical Research1, Paris Descartes University2, University of Rome Tor Vergata3, Boston Children's Hospital4, Ege University5, University of São Paulo6, Marmara University7, American University of Beirut8, Dokuz Eylül University9, Pasteur Institute10, Shahid Beheshti University of Medical Sciences and Health Services11, Rockefeller University12, King Saud University13
TL;DR: Mycobacterial disease is relatively common in patients with CGD living in countries in which tuberculosis is endemic, BCG vaccine is mandatory, or both, and adverse reactions to BCG and severe forms of tuberculosis should lead to a suspicion of CGD.
Abstract: Background Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused by inborn errors of the phagocyte nicotinamide adenine dinucleotide phosphate oxidase complex. From the first year of life onward, most affected patients display multiple, severe, and recurrent infections caused by bacteria and fungi. Mycobacterial infections have also been reported in some patients. Objective Our objective was to assess the effect of mycobacterial disease in patients with CGD. Methods We analyzed retrospectively the clinical features of mycobacterial disease in 71 patients with CGD. Tuberculosis and BCG disease were diagnosed on the basis of microbiological, pathological, and/or clinical criteria. Results Thirty-one (44%) patients had tuberculosis, and 53 (75%) presented with adverse effects of BCG vaccination; 13 (18%) had both tuberculosis and BCG infections. None of these patients displayed clinical disease caused by environmental mycobacteria, Mycobacterium leprae, or Mycobacterium ulcerans. Most patients (76%) also had other pyogenic and fungal infections, but 24% presented solely with mycobacterial disease. Most patients presented a single localized episode of mycobacterial disease (37%), but recurrence (18%), disseminated disease (27%), and even death (18%) were also observed. One common feature in these patients was an early age at presentation for BCG disease. Mycobacterial disease was the first clinical manifestation of CGD in 60% of these patients. Conclusion Mycobacterial disease is relatively common in patients with CGD living in countries in which tuberculosis is endemic, BCG vaccine is mandatory, or both. Adverse reactions to BCG and severe forms of tuberculosis should lead to a suspicion of CGD. BCG vaccine is contraindicated in patients with CGD.
94 citations
••
TL;DR: This review primarily focusses on analyzing the prevalence and drug resistance patterns in the African continent and highlights the prevalence on individual countries in Africa and it is extremely significant to prevent the dissemination of ESBL-producing Enterobacteriaceaea.
94 citations
••
Shahid Beheshti University of Medical Sciences and Health Services1, University of Melbourne2, University of Porto3, Taras Shevchenko National University of Kyiv4, Slovak University of Agriculture5, University of Health Sciences Antigua6, Al-Farabi University7, Graphic Era University8, Canadian Real Estate Association9, University of Concepción10, University of Alabama in Huntsville11, University of Fort Hare12, Zabol University of Medical Sciences13
TL;DR: New insights are provided on myricetin preclinical pharmacological activities, and role in selected clinical trials, which provide new insights on the neuroprotective activity of this flavonoid.
Abstract: Several flavonoids have been recognized as nutraceuticals, and myricetin is a good example. Myricetin is commonly found in plants and their antimicrobial and antioxidant activities is well demonstrated. One of its beneficial biological effects is the neuroprotective activity, showing preclinical activities on Alzheimer, Parkinson, and Huntington diseases, and even in amyotrophic lateral sclerosis. Also, myricetin has revealed other biological activities, among them as antidiabetic, anticancer, immunomodulatory, cardiovascular, analgesic and antihypertensive. However, few clinical trials have been performed using myricetin as nutraceutical. Thus, this review provides new insights on myricetin preclinical pharmacological activities, and role in selected clinical trials.
94 citations
••
TL;DR: It was believed that antibodies targeting PD-1/PD-L1 might synergize with other treatments that enhance endogenous antitumor immunity by blocking inhibitory receptor-ligand interactions, but the host genetic status (as well as that of the tumor) is likely to have an impact on the expected outcomes.
Abstract: The programmed cell death protein 1 (PD-1) is expressed by activated T cells that act as an immunoregulatory molecule, and are responsible for the negative regulation of T cell activation and peripheral tolerance. The PD-1 gene also encodes an inhibitory cell surface receptor involved in the regulation of T cell functions during immune responses/tolerance. Beyond potent inhibitory effects on T cells, PD-1 also has a role in regulating B cell and monocyte responses. An overexpression of PD-1 has been reported to contribute to immune system avoidance in different cancers. In particular, PD-1 over-expression influences tumor-specific T cell immunity in a cancer microenvironment. Blocking the PD-1/PD-1 ligand (PD-L1) pathway could potentially augment endogenous antitumor responses. Along these lines, the use of PD-1/PD-L1 inhibitors has been applied in clinical trials against diverse forms of cancer. It was believed that antibodies targeting PD-1/PD-L1 might synergize with other treatments that enhance endogenous antitumor immunity by blocking inhibitory receptor-ligand interactions. However, in all cases, the host genetic status (as well as that of the tumor) is likely to have an impact on the expected outcomes. Various investigations have evaluated the association between PD-1 polymorphisms and the risk of various types of cancer. Frequently studied PD-1 polymorphisms, PD-1.1 (rs36084323), PD-1.3 (rs11568821), PD-1.5 (rs2227981), PD-1.9 (rs2227982), and PD-1 rs7421861, and their associations in the risk of susceptibility to different types of cancer are mentioned in this review, as are studies highlighting the significance of conducting genetic association studies in different ethnic populations.
93 citations
Authors
Showing all 19557 results
Name | H-index | Papers | Citations |
---|---|---|---|
Paul F. Jacques | 114 | 446 | 54507 |
Mohammad Abdollahi | 90 | 1045 | 35531 |
Fereidoun Azizi | 80 | 1279 | 41755 |
Roya Kelishadi | 73 | 853 | 33681 |
Nima Rezaei | 72 | 1215 | 26295 |
Neal D. Freedman | 68 | 327 | 16908 |
Jamie E Craig | 68 | 380 | 15956 |
Amir Hossein Mahvi | 63 | 686 | 15816 |
Adriano G. Cruz | 61 | 346 | 12832 |
Ali Montazeri | 61 | 625 | 17494 |
Parvin Mirmiran | 56 | 637 | 15420 |
Harry A. Lando | 53 | 242 | 9432 |
Fatemeh Atyabi | 53 | 310 | 9985 |
Daniel Granato | 53 | 235 | 9406 |
Pejman Rohani | 52 | 192 | 13386 |